ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ: ACAD · Real-Time Price · USD

25.61

-0.26 (-1.01%)

At close: Aug 3, 2026, 4:00 PM EDT

25.70

+0.09 (0.35%)

Pre-market: Aug 4, 2026, 4:21 AM EDT

ACADIA Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	282.21	177.7	319.59	188.66	114.85	147.44
Short-Term Investments	569.25	641.99	436.4	250.21	301.98	373.27
Cash & Short-Term Investments	851.46	819.69	755.99	438.87	416.82	520.71
Cash Growth	24.93%	8.43%	72.26%	5.29%	-19.95%	-17.60%
Accounts Receivable	135.35	121.46	98.74	98.27	62.2	64.37
Other Receivables	13.03	26.77	5.96	4.08	0.89	0.98
Total Trade Receivables	148.38	148.23	104.7	102.35	63.08	65.34
Inventory	31.57	34.67	21.95	35.82	6.64	7.88
Other Current Assets	64.6	59.53	55.68	39.09	21.4	23.89
Total Current Assets	1,096	1,062	938.32	616.13	507.94	617.82
Net Property, Plant & Equipment	60.93	54.87	50.79	56.47	61.59	66.32
Other Intangible Assets	106.17	108.89	119.78	65.49	-	-
Other Long-Term Assets	342.12	338.32	78.87	10.87	18.28	15.98
Total Assets	1,605	1,564	1,188	748.96	587.81	700.12

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	12.25	10.9	16.19	17.54	12.75	6.88
Accrued Expenses	293.28	266.21	378.68	236.71	112.88	89.19
Total Current Liabilities	305.52	277.11	394.87	254.25	125.63	96.07
Long-Term Leases	39	40.55	42.04	47.8	52.7	56.13
Other Long-Term Liabilities	12.64	19.14	18.06	15.15	9.07	7.03
Total Long-Term Liabilities	51.64	59.69	60.09	62.95	61.77	63.16
Total Liabilities	357.16	336.81	454.96	317.2	187.4	159.23

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-in Capital	3,058	3,039	2,937	2,863	2,771	2,695
Accumulated Other Comprehensive Income	-0.56	1.45	0.29	0.02	-0.98	-0.19
Retained Earnings	-1,810	-1,813	-2,204	-2,431	-2,370	-2,154
Shareholders' Equity	1,248	1,227	732.79	431.76	400.41	540.89
Total Liabilities & Equity	1,605	1,564	1,188	748.96	587.81	700.12

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	39	40.55	42.04	47.8	52.7	56.13
Net Cash (Debt)	812.46	779.13	713.96	391.07	364.13	464.58
Net Cash Growth	27.56%	9.13%	82.57%	7.40%	-21.62%	-20.92%
Net Cash Per Share	4.75	4.58	4.29	2.39	2.25	2.90
Book Value	1,248	1,227	732.79	431.76	400.41	540.89
Book Value Per Share	7.31	7.22	4.40	2.64	2.48	3.37
Tangible Book Value	1,142	1,118	613.01	366.27	400.41	540.89
Tangible Book Value Per Share	6.68	6.58	3.68	2.24	2.48	3.37

SEC Filings: 10-K · 10-Q